Addictive Behaviours Unit, Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autonoma de Barcelona, Bellaterra, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Addictive Behaviours Unit, Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Int J Drug Policy. 2018 Aug;58:126-134. doi: 10.1016/j.drugpo.2018.06.007. Epub 2018 Jun 26.
Until now, no specific tool has been available to measure heroin-dependent patient satisfaction with buprenorphine-naloxone as a medication. The purpose of the present study was to develop the Scale to Assess Satisfaction with Medications for Addiction Treatment-Buprenorphine-Naloxone for Heroin addiction (SASMAT-BUNHER) and to examine its validity and reliability.
The SASMAT-BUNHER was developed from a pool of 44 self-administered items grouped into nine theoretical domains, as follows: Overall Satisfaction, Pharmacotherapy, Initiation, Anti-Addictive Effect on Heroin, Mental State, Physical State, Personal Functioning, Acceptability, and Anti-Addictive Effect on Secondary Substances. The Treatment Satisfaction Questionnaire for Medication 1.4 version (TSQM 1.4) was used for convergent validation. Participants were 316 heroin-dependent patients in maintenance treatment with buprenorphine-naloxone sublingual tablets at 16 different treatment centres.
Principal component analysis of the SASMAT-BUNHER revealed a 5-factor structure that accounted for 65.1% of total variance. Based on similarities between empirically-obtained factors and theoretical domains, Factors 1 through 5 were named 'Mental and Physical State' (10 items), 'Anti-Addictive Effect on Other Substances' (5 items), 'Anti-Addictive Effect on Heroin' (4 items), 'Personal Functioning' (3 items), and 'Acceptability' (4 items). All factors showed acceptable internal consistency (Cronbach's alpha coefficients: 0.744-0.925) and test-retest reliability (intraclass correlation coefficients: 0.704-0.895). Correlation between SASMAT-BUNHER and TSQM 1.4 total scores was moderate (Pearson r = 0.552). Moreover, SASMAT-BUNHER total scores of patients reporting absence of buprenorphine-naloxone side effects were higher than those of their counterparts.
These results support the validity and reliability of the SASMAT-BUNHER.
到目前为止，还没有专门的工具来衡量海洛因依赖患者对丁丙诺啡-纳洛酮作为一种药物的满意度。本研究的目的是开发评估丁丙诺啡-纳洛酮治疗药物成瘾者满意度的量表（SASMAT-BUNHER），并检验其有效性和可靠性。
SASMAT-BUNHER 是从一组 44 个自我管理项目中开发出来的，这些项目分为九个理论领域，分别是：总体满意度、药物治疗、起始治疗、抗海洛因成瘾效果、精神状态、身体状态、个人功能、可接受性和抗其他物质成瘾效果。采用治疗满意度问卷 1.4 版（TSQM 1.4）进行聚合验证。参与者是来自 16 个不同治疗中心的 316 名接受丁丙诺啡-纳洛酮舌下片维持治疗的海洛因依赖患者。
SASMAT-BUNHER 的主成分分析显示，一个 5 因素结构可以解释总方差的 65.1%。基于实证获得的因素与理论领域之间的相似性，因素 1 至 5 分别命名为“精神和身体状态”（10 个项目）、“抗其他物质成瘾效果”（5 个项目）、“抗海洛因成瘾效果”（4 个项目）、“个人功能”（3 个项目）和“可接受性”（4 个项目）。所有因素均显示出可接受的内部一致性（Cronbach's alpha 系数：0.744-0.925）和重测信度（组内相关系数：0.704-0.895）。SASMAT-BUNHER 与 TSQM 1.4 总分之间的相关性为中等（Pearson r=0.552）。此外，报告丁丙诺啡-纳洛酮无副作用的患者的 SASMAT-BUNHER 总分高于其对照组。
这些结果支持了 SASMAT-BUNHER 的有效性和可靠性。
